COVID-19: What type of cytokine storm are we dealing with?
- PMID: 32681651
- PMCID: PMC7405026
- DOI: 10.1002/jmv.26317
COVID-19: What type of cytokine storm are we dealing with?
Conflict of interest statement
The authors declare that there are no conflict of interests.
Figures
Comment on
-
Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.J Med Virol. 2021 Jan;93(1):120-121. doi: 10.1002/jmv.26209. Epub 2020 Jun 29. J Med Virol. 2021. PMID: 32568411 Free PMC article. No abstract available.
Similar articles
-
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335. Intern Med J. 2021. PMID: 34541767 Free PMC article. No abstract available.
-
Tocilizumab prescribing criteria for COVID-19 patients.Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20. Hum Vaccin Immunother. 2021. PMID: 33079613 Free PMC article. No abstract available.
-
Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.J Med Virol. 2021 Jan;93(1):120-121. doi: 10.1002/jmv.26209. Epub 2020 Jun 29. J Med Virol. 2021. PMID: 32568411 Free PMC article. No abstract available.
-
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954. Rev Recent Clin Trials. 2021. PMID: 32940187 Review.
-
Is IL-6 a key cytokine target for therapy in COVID-19?Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8. Nat Rev Immunol. 2021. PMID: 33850327 Free PMC article. Review.
Cited by
-
Aggravating mechanisms from COVID-19.Virol J. 2024 Sep 27;21(1):228. doi: 10.1186/s12985-024-02506-8. Virol J. 2024. PMID: 39334442 Free PMC article. Review.
-
Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10, MCP-1, and IL-13 in Sepsis Patients.Diagnostics (Basel). 2023 Mar 11;13(6):1069. doi: 10.3390/diagnostics13061069. Diagnostics (Basel). 2023. PMID: 36980378 Free PMC article.
-
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?Drugs. 2023 Jan;83(1):1-36. doi: 10.1007/s40265-022-01803-2. Epub 2022 Dec 12. Drugs. 2023. PMID: 36508116 Free PMC article. Review.
-
Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.World J Crit Care Med. 2022 Jul 9;11(4):269-297. doi: 10.5492/wjccm.v11.i4.269. eCollection 2022 Jul 9. World J Crit Care Med. 2022. PMID: 36051937 Free PMC article.
-
Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.Lancet Respir Med. 2022 Sep;10(9):900-915. doi: 10.1016/S2213-2600(22)00182-5. Epub 2022 Aug 16. Lancet Respir Med. 2022. PMID: 35985357 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources